Inhaled Pentamidine for Bolivian Mucosal Leishmaniasis
- 7 May 2025
- journal article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 112 (5) , 963-965
Abstract
: Aerosolized pentamidine is Food and Drug Administration approved to treat Pneumocystis pneumonia via a route that does not lead to systemic absorption or toxicity. Because Leishmania is also susceptible to pentamidine and mucosal leishmaniasis is also an infection of the respiratory tract, we performed a pilot study of aerosolized pentamidine (300 mg for 10 days over approximately 4 weeks) for mucosal leishmaniasis caused by Bolivian Leishmania braziliensis with a 2-year follow-up. Of 15 patients, 6 of 7 patients with initially mild disease were cured, 3 of 4 patients with initially moderate disease relapsed at the 18- to 24-month follow-up visits, and 3 of 4 patients with initially severe disease failed early after treatment. This study suggests that inhaled pentamidine may be useful as a well-tolerated treatment of mild mucosal leishmaniasis and that to rule out relapse, mucosal leishmaniasis follow-up should extend to 2 years.Keywords
This publication has 7 references indexed in Scilit:
- The cure rate after different treatments for mucosal leishmaniasis in the Americas: A systematic reviewPLOS Neglected Tropical Diseases, 2022
- Mucosal leishmaniasis: A Retrospective Study of 327 Cases from an Endemic Area of Leishmania (Viannia) braziliensisThe American Journal of Tropical Medicine and Hygiene, 2017
- Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)The American Journal of Tropical Medicine and Hygiene, 2017
- Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. An Italian multicentric randomised controlled trialJournal of Infection, 1995
- Spontaneous clinical resolution without specific treatment in mucosal leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 1991
- Efficacy and Toxicity of Sodium Stibogluconate for Mucosal LeishmaniasisAnnals of Internal Medicine, 1990
- Cell mediated immunity in American cutaneous and mucosal leishmaniasis.The Journal of Immunology, 1985